Rhythm Pharma: Investible Based On Upcoming Trial Data

Summary

RYTM has four phase 3 trials ongoing in related genetic obesity diseases.

These have each seen positive proof of concept data.

The company has decent cash runway and very little competition.

This idea was discussed in more depth with members of my private investing community, The Total Pharma Tracker. Start your free trial today »

Rhythm Pharma (RYTM) is a relatively underfollowed company with an ongoing phase 3 trial of lead (and only) drug setmelanotide in two obesity-related syndromes, Bardet-Biedl Syndrome (BBS) and Alström Syndrome, where enrollment will be completed in late 2019, and two other genetic obesity syndromes, Leptin Receptor Deficiency Obesity (LEPR) and POMC deficiency obesity, where phase 3 data will be out by 2019.

Setmelanotide targets the MC4 pathway, which regulates weight by increasing metabolism and reducing appetite. When this pathway is affected by genetic mutations, it can lead to its malfunction, causing early onset obesity, hyperphagia and other related symptoms of genetic obesity, leading to “vision loss, polydactyly, kidney abnormalities, and other symptoms.”

Genetic early onset obesity and its related syndromes is the same disease area where Zafgen’s Beloranib once failed to achieve success; setmelanotide, however, targets melanocortin-4 while Beloranib targeted a different enzyme called METAP2. They also target entirely different syndromes - beloranib focused on Prader-Willi syndrome. In 2018, Rhythm came up with positive trial results from a midstage study, while mostly avoiding the telltale signs of safety issues that vexed Zafgen. So we ran it through our IOMachine, a proprietary four factor test checking for catalysts, prior trials, cash and competition, to determine if the company is investment-grade. Here are the results.

READ FULL ARTICLE HERE